AIMS. The investigators will study the relationship of the new osteocyte-derived biomarkers of bone disease, FGF23 (and klotho) and sclerostin, with bone histologic changes and CV events at baseline and one year after transplantation. If an association is to be found, the performance of the biomarkers as predictors of CKD-MBD will be determined.